Top news of the week: 10.02.2022.
Career And Jobs
Gamida, Unity Layoffs Illustrate Challenges Faced by Small Biotech
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
Another microcap biotech plots major job cuts as industry sharpens its axe amid slowdown
Amid biotech's ugly start to the year, you can barely throw a stone without hitting a bad headline. Now, another microcap firm is gutting its workforce to help keep the lights on. Unity ...
Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered ...
UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in...
Sartorius completes acquisition of Novasep’s chromatography equipment division
Sartorius completes acquisition of Novasep’s chromatography equipment division An opportunity for Novasep’s chromatography equipment division to accelerateits growth by joining ...
Who are the young biopharma leaders shaping the industry in 2022? Nominate them for Endpoints' special report
Drug development can sometimes seem like a middle-aged game, but oftentimes the inspiration for the industry's biggest innovations came when its creators were far younger. Take CAR-T, the ...
Lyell CSO: New job is 'the missing piece' of his career; Orphazyme and Cortexyme and Sio, oh my: Your guide to the latest CEO changes
“I fully recognize that cell therapy is still all about the cells.” In moving over to his second CSO job, Gary Lee says he hopes to grasp a
Two Pandion vets jump back into the startup world, this time using machine learning to build better immunology drugs
As her days as a Merck employee dwindled down and the uncertain next step of her career stared her in the face, Jo Viney felt a sense of a job left undone. Not at Merck, mind you, but at ...